Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Colleen Kersgard

Hematology & Oncology Palmer, AK Medical Doctor

NPI 1194875831 CMS profile 795838

2490 S Woodworth Loop Ste 499, Palmer, AK 99645

Open in the dashboard

General payments

$490

15 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Colleen Kersgard of Palmer, AK is reported in the CMS Open Payments database as having received $490 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 27th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $380 12
2024 General $15 1
2023 General $96 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Colleen Kersgard
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Colleen Kersgard were reported at $380. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Colleen Kersgard Hematology & Oncology median Middle half National median
2019 $0 $529 $121–$2,516 $163
2020 $0 $339 $82–$2,213 $114
2021 $0 $263 $49–$1,965 $132
2022 $0 $416 $103–$2,395 $149
2023 $96 $542 $125–$2,646 $160
2024 $15 $692 $141–$3,008 $164
2025 $380 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $138 5 payments
  2. Janssen Biotech, Inc. $125 2 payments
  3. Intuitive Surgical, Inc. $105 1 payment
  4. GlaxoSmithKline, LLC. $49 3 payments
  5. Mirati Therapeutics, Inc. $21 1 payment
  6. Exelixis Inc. $19 1 payment
  7. Pharmacosmos Therapeutics Inc. $19 1 payment
  8. Daiichi Sankyo Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $469 14 payments
  2. Education $21 1 payment
Products named General payments · program years 2023–2025
  1. CARVYKTI $108 1 payment
  2. RYBREVANT $108 1 payment
  3. Da Vinci Surgical System $105 1 payment
  4. IMFINZI $75 1 payment
  5. LYNPARZA $34 2 payments
  6. JEMPERLI $31 2 payments
  7. ZEJULA $31 2 payments
  8. KRAZATI $21 1 payment
  9. CABOMETYX $19 1 payment
  10. MONOFERRIC $19 1 payment
  11. Other $67 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

514

Median for Hematology-Oncology: 604

Drug cost

$660,888

Median for Hematology-Oncology: $1,306,514

Branded share of claims

14.4%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 41 $581,193
Imatinib Mesylate Generic 35 $68,400
Dexamethasone Generic 35 $2,980
Anastrozole Generic 79 $1,838
Hydroxyurea Generic 46 $1,727
Tamoxifen Citrate Generic 40 $1,091
Ondansetron Hcl Generic 38 $977
Letrozole Generic 42 $857
Prochlorperazine Maleate Generic 30 $550
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $402

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$2,915,789

Of which drugs: $2,669,155

Medicare patients

501

Average age 73

Services billed

170,912

291 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Cancer 50%
Arthritis 44%
Diabetes 30%
Ischemic heart disease 27%
COPD 23%
Atrial fibrillation 20%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 18 15,800 $705,156
Injection, denosumab, 1 mg J0897 Office 30 15,120 $301,821
Injection, iron dextran, 50 mg J1750 Office 11 430 $5,881
Injection, alteplase recombinant, 1 mg J2997 Office 13 40 $2,618
Injection, zoledronic acid, 1 mg J3489 Office 16 177 $844
Injection, palonosetron hcl, 25 mcg J2469 Office 34 1,120 $809
Injection, carboplatin, 50 mg J9045 Office 13 284 $793
Injection, fosaprepitant, 1 mg J1453 Office 18 6,600 $729
Injection, fluorouracil, 500 mg J9190 Office 13 312 $685
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 68 3,920 $328

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record